Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab in Frontline Treatment of Advanced Classical Hodgkin Lymphoma
NCT03617666Phase 2Active, not recruiting
- Sponsor
- University College London
- Start
- Sep 2019
- Primary completion
- Jul 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 2 trial of avelumab in classical Hodgkin lymphoma (cHL), sponsored by University College London. Started Sep 2019; status: active, not recruiting.
02
Drugs
avelumab
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT03617666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03617666.